As investors, food companies and regulators are increasingly treating alternative protein categories as scalable inputs, two once-niche categories in food are moving from R&D curiosity toward commercial reality. The alternative protein conversations of 2025 have stopped being purely theoretical as the industry moves into 2026. Insect and algae proteins, in fact, are seeing a shift in acceptance, as regulatory wins, industrial-scale supply models and clearer use-cases are driving the industry. Although consumer acceptance and unit economics remain work-in-progress, insect and algae proteins are being seen more and more in animal feed, pet food and specialty ingredients. 

Here are the key trends shaping the insect and algae corners of the alternative protein market:

 

REGULATORY PROGRESS IS UNLOCKING COMMERCIAL PATHWAYS — BUT UNEVENLY

2025 saw a steady trickle of regulatory green lights for insect ingredients, particularly in the EU, which remains a focal point for novel food approvals. Over the last few years, the European Food Safety Authority (EFSA) and the European Commission have cleared multiple insect ingredients (mealworm, crickets and other preparations), and more approvals landed recently through 2024–2025 — clearing the way for wider retail and ingredient use across Europe. That patchwork of approvals is making it easier for European processors and ingredient firms to commercialize products; but approvals vary by species, form (whole vs. powder) and jurisdiction, so cross-border scale still requires legal and labeling work.

A handful of boutique approvals in 2025 (for example a UV-treated mealworm powder authorized for sale under EU novel food rules) shows how niche product innovations like processing methods and safety dossiers can unlock temporary exclusive commercialization windows for specific companies. But regulatory progress has not instantly translated to mass retail shelves for humans, as most commercial volumes today are targeted at feed and pet channels. 

At the same time, regulatory frameworks are settling for algae-derived ingredients like seaweed extracts, microalgae protein isolates and pigments, which makes it easier for food formulators to trial algae in snacks, dairy alternatives and functional ingredients. Regulatory clarity lowers uncertainty for ingredient buyers and retailers, which is one of the biggest commercial barriers in the industry.

 

COMMERCIAL SCALE IS REAL — ESPECIALLY FOR FEED AND PET FOOD

Several industrial players are operating commercial facilities that process billions of larvae per production cycle, with business models built around converting low value byproducts and food waste into protein and oil streams for animal feed and pet food. These vertically integrated, high-throughput farms are attracting strategic partners from the global agriculture and ingredient sector. That focus on feed/pet markets is pragmatic as regulatory hurdles are lower, contract sizes are larger and economics are nearer term than human food products. 

At the same time, some insect companies have faced financial strain while scaling, forcing restructurings or strategic pivots. This has demonstrated that building cost-competitive insect protein at commodity scale remains a hard engineering and capital problem. 

 

TWO SEPARATE COMMERCIAL PATHWAYS: FEED AND PET FOOD FIRST; HUMAN FOOD LATER

The fastest, most resilient route to market for insect proteins continues to be animal feed and pet food. Feed buyers value protein quality, regulatory safety and carbon/water/land footprint — and they tolerate higher ingredient prices when those ingredients solve sustainability or supply-chain problems (e.g., replacing overfished forage fish or high-deforestation soy in specialized diets). For algae, food-grade extracts and proteins have found traction both as functional ingredients and as nutritional boosters in human foods. But like insects, algae is also scaling faster in niche supplement, beverage and pet food segments. Market analysts project meaningful compound annual growth rate (CAGR) growth over the next decade for both insect and algae industries. 

Human food applications including snack bars, baked goods and meat extenders are growing — but broadly, human-facing uses still need sustained price declines, taste/texture optimization and consumer-facing education campaigns.

 

CIRCULARITY AND VERTICAL INTEGRATION ARE CENTRAL COMMERCIAL PLAYS

One of insect protein’s strongest selling points is circularity, as some insect larvae can consume byproducts and side streams. This turns them into high value protein and lipid. Leading farms are designing integrated energy and waste flows (like heat reuse, waste inputs from nearby processors) to improve unit economics and carbon footprints. This systems approach — linking waste management, feed input and on-site processing — is increasingly treated as a commercial moat.

For algae, closed photobioreactor systems and co-location with industrial carbon dioxide sources or wastewater treatment are similarly attractive strategies to reduce production cost and improve sustainability metrics. Both sectors are proving that biological inputs alone are not enough though, and that operational engineering, materials science and logistics matter equally. 

 

MONEY IS MORE DISCIPLINED — CAPITAL CHASES DURABILITY AND INTEGRATION

After the exuberant funding environment earlier in the decade, investors in food and beverage brands are being more selective. The market still shows solid upside in forecasts, but funders increasingly prefer companies with clear routes to revenue. This comes from having proven supply contracts, integration with waste or energy systems, or partnerships with incumbents. Having this means more investment into industrialization (such as farms, processing plants and extraction technology) and fewer speculative consumer-brand plays without supply stability. This shift favors firms that can demonstrate cost trajectories and regulatory compliance. Market estimates vary, but most forecasts still predict double-digit growth rates for insect protein and steady expansion for algae protein across 2025–2035. 

 

CHALLENGES FACING THE FOOD SECTOR IN ALTERNATIVE PROTEINS

Food and beverage manufacturers hoping to explore alternative proteins now or in the future should be aware of existing constraints, while still noting that progress will likely happen:

  • Unit Economics: The single biggest barrier to broad consumer adoption remains unit cost. Insects and specialty algae extracts are often more expensive than commodity soy or fishmeal, and price parity depends on further scale and process efficiency. Most independent market reports show insect and algae protein markets are growing from modest bases (hundreds of millions–low billions USD in 2024) with healthy CAGRs projected, but cost-competitiveness against soy, pea or crude fishmeal is still an imperative for mass adoption. Continued reductions in production cost, automation, and integrations with waste streams or carbon dioxide sources will determine how quickly those CAGRs translate into real supermarket volumes.
  • Consumer Acceptance: In Western human food markets, insects still face cultural resistance; clean-label insect ingredients like flours and isolates and neutral-flavored algae isolates can help, but education and familiarity take time. Consumer willingness to try algae is higher than for insects in many markets due to familiarity (spirulina smoothies, seaweed snacks) and clearer health narratives. Insect-based human foods still face perceptual hurdles, so many brands are focusing on invisible inclusion (powders, flours, protein concentrates) rather than whole-insect products. They are also prioritizing business-to-business ingredient sales where the consumer does not see the production story. Market success in 2025 is increasingly about taste, price parity and storytelling (such as around safety, sustainability and provenance).
  • Regulatory Patchwork: While the EU’s novel food approvals and specific country-level authorizations are clearing a path, regulatory regimes still vary globally; companies must navigate a complex landscape to expand internationally. 

Alternative proteins are proving its commercial niche first in animal feed/pet food as well as multifunctional ingredients, with a slowly widening set of human food approvals and product launches. Partnerships between startups, established food companies and investors focused on concrete unit economics will determine whether insects and algae become mainstream protein inputs or valuable niche suppliers.

Investors, ingredient buyers and policymakers should watch for three signals in the next year or two that will decide whether these sectors accelerate beyond niche status: 

  1. Continued cost declines from scale
  2. A widening set of regulatory approvals in key markets
  3. A set of profitable, repeatable supply contracts with major feed or food companies

GHJ’s Food and Beverage Practice is here to advise business leaders on their strategic options for expanding into new sectors, experimental niches and specialty ingredients. Learn more about your opportunities for 2026 and beyond by contacting GHJ.